Navigation Links
MultiVu Video Feed: Geron Receives FDA Clearance to Begin World's First Human Clinical Trial of Embryonic Stem Cell-Based Therapy
Date:1/23/2009

Geron to Study GRNOPC1 in Patients with Acute Spinal Cord Injury

Geron Corporation (Nasdaq: GERN) announced that the U.S. Food and Drug Administration (FDA) has granted clearance of the company's Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury. The clearance enables Geron to move forward with the world's first study of a human embryonic stem (hESC) cell-based therapy in man.

Geron plans to initiate a Phase I multicenter trial that is designed to establish the safety of GRNOPC1 in patients with "complete" American Spinal Cord Injury Association (ASIA) Grade A subacute thoracic spinal cord injuries. Patients eligible for the Phase I trial must have documented evidence of functionally complete spinal cord injury with a neurological level of T3 to T10 spinal segments and agree to have GRNOPC1 injected into the lesion sites between seven and 14 days after injury.

    For more information about GRNOPC1, please visit:http://www.geron.com

    SATELLITE FEEDS:
    Friday, January 23rd, 2009         Friday, January 23rd, 2009
    9:30 AM - 9:45 AM ET               1:15 PM - 1:30 PM ET
    Galaxy 3C                          Galaxy 3C
    C-Band                             C-Band
    Transponder 8                      Transponder 8
    Downlink Freq. 3860 Vertical       Downlink Freq. 3860 Vertical

Preview and access this video on Pathfire DMG: Slug # 33040

Search within the PR Newswire or MultiVu section by story ID # 33040 or by headline

For technical assistance call Pathfire Customer Care at 1-888-345-0489 or e-mail support@pathfire.com

NEWS: World's First Study of Human Embryonic Stem Cell-Based Therapy In Man

FORMAT: B-roll and Soundbites

ADDITIONAL RESOURCES: Video, contact information and more available at: http://www.prnewswire.com/broadcast/33040/press.html


    SOUNDBITES:
    * Thomas B. Okarma, Ph.D., M.D., President, CEO and Director, Geron
      Corporation

    B-ROLL INCLUDES:
    * spinal cord cell therapy animation
    * lab and manufacturing footage
    * Geron office building exterior shots

VIDEO PROVIDED BY: Geron Corporation

Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3


'/>"/>
SOURCE Geron Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MultiVu Video Feed: U.S Food and Drug Administration (Fda) Approves Latisse(TM) --
2. MultiVu Video Feed: New Rapid Test to Diagnose Flu May Help With Upcoming Flu Season
3. MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care
4. MultiVu Video Feed: Easypod(R), Award-Winning Electronic Device
5. MultiVu Video Feed: Hard Rocks 2007 Ambassadors of Rock Tour Is "On the Road Again" With Music Legend Willie Nelson
6. MultiVu Video Feed: Allergan, Inc. Partners With "Project Runway" Designer Kara Saun and Gen Art Fresh Faces In Fashion to Raise Awareness About Excessive Underarm Sweating
7. New Video Streaming Site Created by Ambrose Video Publishing
8. Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes
9. New Online Video Features Brazilian Researcher Elbio Rech
10. Video: 8-Minute Film Documentary Explores Why Humans Age
11. PharmSource President Moderates Videocast on Outsourcing to Asia at AAPS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 20, 2017 Stock-Callers.com explores the ... influenced the most recent performances of select equities. In ... RGLS ), Abeona Therapeutics Inc. (NASDAQ: ... ), and Sage Therapeutics Inc. (NASDAQ: SAGE ... View Research, global Biotech market size is expected to reach $604.40 billion by ...
(Date:1/19/2017)... Jan 19, 2017 Research and Markets has ... Technology, Biomolecules, Cancer Type, Application - Global Opportunity Analysis and Industry ... ... the global market is projected to reach $15,737 million by 2022 ... 2016 to 2022. Omic technologies segment accounted for ...
(Date:1/19/2017)... Research and Markets ... announced the addition of the "Implantable Biomaterials Market ... report to their offering. Report Highlights: ... analysis on current and future market trends to identify the investment opportunities ... the base numbers Key market trends across the business ...
(Date:1/19/2017)... 19, 2017  ArmaGen, Inc., today announced that ... as chief executive officer, as well as a ... to ArmaGen more than 17 years of executive ... of biotherapeutics and pharmaceuticals. "Mathias ... experience and skillset necessary to lead ArmaGen to ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 15, 2016   WaferGen Bio-systems, Inc. ... genomics technology company, announced today that on December 13, ... Department of The Nasdaq Stock Market LLC which acknowledged ... price of WaferGen,s common stock had been at $1.00 ... has regained compliance with Listing Rule 5550(a)(2) of the ...
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in ... biometrics market" The mobile biometrics market is expected to ... 49.33 billion by 2022, at a CAGR of 29.3% ... factors such as the growing demand for smart devices, ... transactions. "Software component is expected to grow ...
(Date:12/7/2016)... According to a new market research report "Emotion Detection and Recognition Market ... Application Area, End User, And Region - Global Forecast to 2021", published by ... 2016 to USD 36.07 Billion by 2021, at a Compound Annual Growth Rate ... ... MarketsandMarkets Logo ...
Breaking Biology News(10 mins):